| Ytd | 38.35% | |
| 1y | 86.42% |
| Open | 17.57 | Prev Close | 17.59 | Low | 17.24 | High | 17.57 | Mkt Cap | 20.48B |
| Vol | 4.23M | Avg Vol | 10.98M | EPS | 2.45 | P/E | 7.18 | Forward P/E | 6.60 |
| Beta | 0.91 | Short Ratio | 4.83 | Inst. Own | 88.26% | Dividend | 0.48 | Div Yield | 2.78 |
| Ex Div Date | 05-22 | Earning | 08-06 | 50-d Avg | 16.37 | 200-d Avg | 13.65 | 1yr Est | 17.81 |
Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at e
Investors turn to dividend-yielding stocks during market turbulence. Benzinga's Analyst Stock Ra
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi
Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and
Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare set
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt
Does Viatris (VTRS) have what it takes to be a top stock pick for momentum investors? Let's find out
PITTSBURGH, July 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, t
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t
Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst rati
VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well ToleratedVR-205 Efficacy and Sa
VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated VR-205 Efficacy and S
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi
Viatris Inc. ends the first half of 2026 on a high note. On May 8, its stock reached a 52-week high
Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and
Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth driv
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t
Compare expense ratios, diversification, and risk profiles as these two value-focused ETFs take dist
A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare fu
VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decisio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t
FDA PDUFA Goal Date Set for Dec. 27, 2026 PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nas
Health officials explored restricting specific antidepressants among SSRI drugs-sources
https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men
Investors turn to high-yielding dividend stocks in turbulent markets. Benzinga readers can check ana
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings a
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
On Thursday, 1076 companies hit new 52-week lows.